Cantargia completes recruitment and reports positive interim update in CAN04 pancreatic cancer combination therapy
Cantargia AB today announced that all 31 pancreatic cancer (PDAC) patients planned in the CANFOUR trial investigating combination of CAN04 and chemotherapy have started treatment. In the interim data set, no unexpected side effects have been reported, but notably fatigue and neuropathy were less common than reported from chemotherapy, while neutropenia was more common. With partial responses so far documented in 8 out of 20 (40%) evaluable patients, response rates are higher than expected from historical control data with chemotherapy alone. The responses have been durable for longer than 1